J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.

Chronic health conditions can be debilitating, and skin conditions in particular can make sufferers dread things like going to work, running errands or spending time outdoors. Millions suffer from ...

Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a clinical trial, scientists found that a Mediterranean diet could ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...

"Walking around with this very visible, very robust ailment has a pretty tremendous impact on your mental health," Maddox Patt tells PEOPLE ...

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.